Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$2.3B
75M shares
52-week range
$10.95 – $31.59
96% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
P/S (TTM)
9.0
Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.
www.schrodinger.comNo one on the platform currently holds SDGR.
| Institution | Shares | Reported |
|---|---|---|
| Bridgewater Associatesas of 2024-06-30 | 87,113 | $1.7M |
No one on the platform has traded SDGR yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | — | — | — | |||
| Rev. Growth % | 23.3% | 18.8% | ||||
| Profit Margin % | -40.4% | -53.4% | ||||
| Free Cash Flow Margin % | 4.9% | -54.2% | ||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
$SDGR Out at $31... which probably means a 2X in the coming weeks 😂 GLTA
View on StockTwits ↗
$SDGR wer wohl sammelt Lilly vieleicht Es bleibt eine wette auf ein BUYOUT
View on StockTwits ↗$SDGR Es werden viele Aktien wohl getauscht,Irgendwie hab Ich das Gefühl ,da ist was in Planung
View on StockTwits ↗$SDGR WerBranchenführer in der Molekularbiologie in Verbindung mit KI zu sein scheint, und grosses Interesse bei vielen Big Pharma Unternehmen zu wecken ,ist ein heisser Übernahme Kandidat auf Dauer ,.!!! Welche Mk würde es wert sein ? 《~20Mrd vieleicht 》 Börse wertet Zukunft.
View on StockTwits ↗
$SDGR short here short here blah blah blah. Moron. This is going up mark.my words.
View on StockTwits ↗$SDGR 31 $ und der Kurs ist festgesetzt ,die grossen wollen die kurzfristigen Anleger wohl rauskicken. Ich sehe nach der Firmengründung 45 - 50 € Warten und bei Rücksetzer zukaufen ,gegen den Strom eben .
View on StockTwits ↗
$SDGR selling at a high. Rates will rise next month, and their cashflow sucks. Good luck!
View on StockTwits ↗$SDGR Bin positiv gestimmt ,wie wenig hier bisher sich ausgetauscht wird ,ein Zeichen das noch kaum Private diese Perle kennen . Gestern war noch ein grösserer Finalumsatz ,es wird noch weiter getauscht , Guten Start heute SDGR FREUNDE!!!
View on StockTwits ↗
$SDGR Und kommt noch ein grosser Umsatz wie die letzten wochen .? Grosse Käufer am Start?
View on StockTwits ↗$SDGR Ramy Farid hält die Firma auf Kurs Weiter so und es kommen noch viele gute News Davon bin Ich überzeugt .
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $243M | -3.8% | $-1.60 | $-1.66–$-1.55 | — | 3 |
| 2027 | $250M | +3.1% | $-1.42 | $-1.56–$-1.26 | — | 3 |
| 2028 | $280M | +11.9% | $-0.91 | $-1.64–$-0.34 | — | 3 |
| 2029 | $372M | +32.7% | $-0.01 | $-0.01–$-0.01 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 5 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-05 | $-0.41 | $0.08 | +119.3% |
| 2026-05-05 | $-0.56 | $-0.81 | -44.6% |
| 2026-02-25 | $-0.13 | $0.44 | +438.5% |
| 2025-11-05 | $-0.75 | $-0.45 | +40.0% |
| 2025-08-06 | $-0.83 | $-0.59 | +28.9% |
| 2025-05-07 | $-0.71 | $-0.82 | -15.5% |
| 2025-02-26 | $-0.35 | $-0.55 | -57.1% |
| 2024-11-12 | $-0.60 |
| $-0.52 |
| +13.3% |
| $2.4B |
| — |
| OMCLOmnicell, Inc. | $32.43 | +0.62% | $1.5B | — |
| OMDAOmada Health | $20.61 | +0.88% | $1.2B | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.